Stock STX SHIELD THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shield Therapeutics plc

Equities

STX

GB00BYV81293

Delayed London S.E.
Other stock markets
 10:14:01 2024-04-26 am EDT 		5-day change 1st Jan Change
1.3 GBX +6.12% Intraday chart for Shield Therapeutics plc -11.86% -80.60%
Feb. 22 Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024
Feb. 21 FTSE 100 takes hit ahead of FOMC minutes AN

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • With regards to fundamentals, the enterprise value to sales ratio is at 1 for the current period. Therefore, the company is undervalued.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SHIELD THERAPEUTICS PLC Stock Shield Therapeutics plc
-80.60% 11.97M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.38% 103B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.89% 95.71B
B+
ARGENX SE Stock argenx SE
+2.04% 22.02B
B
BIONTECH SE Stock BioNTech SE
-16.83% 20.9B
B+
GENMAB A/S Stock Genmab A/S
-8.98% 17.85B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.62% 15.52B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.69% 13.86B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.35% 12.04B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. STX Stock
  4. Ratings Shield Therapeutics plc